Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioGross MarginInvested CapitalMarket Capitalization

Mainz Biomed N.V (MYNZ) EBIT Margin: 2022-2023

Historic EBIT Margin for Mainz Biomed N.V (MYNZ) over the last 2 years, with Dec 2023 value amounting to -3,068.71%.

  • Mainz Biomed N.V's EBIT Margin rose 127159.00% to -3,068.71% in Q4 2023 from the same period last year, while for Dec 2023 it was -2,975.47%, marking a year-over-year increase of 201513.00%. This contributed to the annual value of -2,091.23% for FY2024, which is 88424.00% up from last year.
  • As of Q4 2023, Mainz Biomed N.V's EBIT Margin stood at -3,068.71%, which was up 1.17% from -3,104.90% recorded in Q3 2023.
  • Mainz Biomed N.V's 5-year EBIT Margin high stood at -2,593.94% for Q1 2023, and its period low was -5,657.13% during Q3 2022.
  • Moreover, its 2-year median value for EBIT Margin was -3,762.09% (2023), whereas its average is -4,067.33%.
  • Data for Mainz Biomed N.V's EBIT Margin shows a peak YoY surged of 300,598bps (in 2023) over the last 5 years.
  • Quarterly analysis of 2 years shows Mainz Biomed N.V's EBIT Margin stood at -4,340.30% in 2022, then spiked by 127,159bps to -3,068.71% in 2023.
  • Its EBIT Margin was -3,068.71% in Q4 2023, compared to -3,104.90% in Q3 2023 and -3,183.87% in Q2 2023.